Investments
111Portfolio Exits
40About Boxer Capital
Boxer Capital is a vehicle for Tavistock Life Science's investment in a portfolio of public companies and private equity crossover opportunities. Boxer Capital leverages its internal expertise in evaluating pre-clinical and clinical data to generate outsized returns for company founders and employees as well for its investor the Tavistock Group. Boxer Capital has a focus on biotechnology drug development companies across multiple therapeutic indications.
Boxer Capital Headquarter Location
P.O. Box 9000
Windermere, Florida, 34786,
United States
Latest Boxer Capital News
Jan 19, 2022
Ceptur Therapeutics, Inc. (“Ceptur”), a biotechnology company focused on developing targeted oligonucleotide therapeutics based on U1 Adaptor technology, today announced the completion of a $75M Series A financing. The round was co-led by venBio Partners and Qiming Venture Partners USA with participation by new investors Perceptive Xontogeny Venture (PXV) Fund, Bristol Myers Squibb and Janus Henderson Investors along with existing Seed investors Affinity Asset Advisors, Boxer Capital and LifeSci Venture Partners. The post Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology appeared first on BioBuzz.
Boxer Capital Investments
111 Investments
Boxer Capital has made 111 investments. Their latest investment was in Ceptur Therapeutics as part of their Series A on January 1, 2022.
Boxer Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
1/19/2022 | Series A | Ceptur Therapeutics | $75M | Yes | 3 | |
1/14/2022 | Series A | Alterome Therapeutics | $64M | Yes | Nextech Invest, OrbiMed Advisors, Undisclosed Investors, and Vida Ventures | 4 |
11/3/2021 | Series B | Shoreline Biosciences | $140M | No | 2 | |
9/1/2021 | Series B | |||||
6/1/2021 | Series B |
Date | 1/19/2022 | 1/14/2022 | 11/3/2021 | 9/1/2021 | 6/1/2021 |
|---|---|---|---|---|---|
Round | Series A | Series A | Series B | Series B | Series B |
Company | Ceptur Therapeutics | Alterome Therapeutics | Shoreline Biosciences | ||
Amount | $75M | $64M | $140M | ||
New? | Yes | Yes | No | ||
Co-Investors | Nextech Invest, OrbiMed Advisors, Undisclosed Investors, and Vida Ventures | ||||
Sources | 3 | 4 | 2 |
Boxer Capital Portfolio Exits
40 Portfolio Exits
Boxer Capital has 40 portfolio exits. Their latest portfolio exit was Tyra Biosciences on September 15, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
9/15/2021 | IPO | 4 | |||
8/5/2021 | Acquired | 13 | |||
7/29/2021 | IPO | 2 | |||
Date | 9/15/2021 | 8/5/2021 | 7/29/2021 | ||
|---|---|---|---|---|---|
Exit | IPO | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 4 | 13 | 2 |
Boxer Capital Team
5 Team Members
Boxer Capital has 5 team members, including current Senior Vice President, Dominik Naczynski.
Name | Work History | Title | Status |
|---|---|---|---|
Dominik Naczynski | Senior Vice President | Current | |
Norman Zhou | Senior Vice President | Current | |
Mac Dabah | Managing Director | Current | |
Christopher Fugelsang | Managing Director | Current | |
Christopher Fuglesang | Tavistock Group, Perkins Coie, and Eidogen-Sertanty | Founder | Former |
Name | Dominik Naczynski | Norman Zhou | Mac Dabah | Christopher Fugelsang | Christopher Fuglesang |
|---|---|---|---|---|---|
Work History | Tavistock Group, Perkins Coie, and Eidogen-Sertanty | ||||
Title | Senior Vice President | Senior Vice President | Managing Director | Managing Director | Founder |
Status | Current | Current | Current | Current | Former |